Literature DB >> 10631114

Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.

N Chikatsu1, Y Takeuchi, Y Tamura, S Fukumoto, K Yano, E Tsuda, E Ogata, T Fujita.   

Abstract

Cancer cells metastasized to bone induce osteoclastogenesis for bone destruction. Coculture of either mouse melanoma B16 or breast cancer Balb/c-MC cells with mouse bone marrow cells (BMCs) induced osteoclast-like cells, which were not observed when cancer cells were segregated from BMCs. Osteoclast differentiation factor (ODF), also known as receptor activator of NF-kappaB ligand (RANKL), is a direct mediator of many osteotropic factors. Neither BMCs, B16 nor Balb/c-MC cells alone expressed ODF mRNA. However, coculture of these cancer cells with BMCs induced ODF expression, which was prevented by indomethacin. Moreover, the coculture with cancer cells inhibited secretion of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF), an inhibitory decoy receptor for ODF, from BMCs. Thus, enhanced osteoclastogenesis in the presence of cancer cells might be due to an increase in ODF activity. These results suggest that interactions between cancer cells and BMCs induce ODF expression and suppress OPG/OCIF level in metastatic foci resulting in pathological osteoclastogenesis for bone destruction. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10631114     DOI: 10.1006/bbrc.1999.2008

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

1.  Osteolysis and cancer.

Authors:  D Goltzman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling.

Authors:  Bokyung Sung; Sung-Gook Cho; Mingyao Liu; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

3.  Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.

Authors:  Guenther G Steger; Rupert Bartsch
Journal:  Ther Adv Med Oncol       Date:  2011-09       Impact factor: 8.168

4.  WITHDRAWN: Cardamonin Inhibits Osteoclastogenesis Induced by Tumor Cells Through Interruption of the Signaling Pathway Activated by Receptor Activator of NF-κB Ligand.

Authors:  Vivek R Yadav; Sahdeo Prasad; Simone Reuter; Bokyung Sung; Norio Yamamoto; Akira Murakami; Bharat B Aggarwal
Journal:  Cancer Lett       Date:  2011-12-17       Impact factor: 8.679

5.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Authors:  J Zhang; J Dai; Y Qi; D L Lin; P Smith; C Strayhorn; A Mizokami; Z Fu; J Westman; E T Keller
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

6.  Breast Cancer: Rank Ligand Inhibition.

Authors:  Rupert Bartsch; Guenther G Steger; Michael Gnant; Reinhard Ziebermayr
Journal:  Breast Care (Basel)       Date:  2010-10-15       Impact factor: 2.860

7.  Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells.

Authors:  Tomoko Okada; Shingo Akikusa; Hiroaki Okuno; Masato Kodaka
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Authors:  Eva Grimaud; Luc Soubigou; Séverine Couillaud; Patrick Coipeau; Anne Moreau; Norbert Passuti; François Gouin; Françoise Redini; Dominique Heymann
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 9.  Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer.

Authors:  Lauren Bassaro; Stephen J Russell; Elzbieta Pastwa; Stella A Somiari; Richard I Somiari
Journal:  Cancer Genomics Proteomics       Date:  2017 Nov-Dec       Impact factor: 4.069

10.  Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.

Authors:  T Ohshiba; C Miyaura; M Inada; A Ito
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.